Fig. 2From: Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug reviewNumber of CDR submissions for drugs for rare diseases by indicated disease prevalence. Numbers above columns indicate the number of submissionsBack to article page